Red blood cell distribution width as a prognostic factor in patients with aplastic anemia treated with cyclosporin A plus androgen or cyclosporine A alone: a retrospective study

Figures & data

Table 1. Clinical characteristics.

	Total	RDW ≥ 15%	RDW < 15%	P
Age (years)
Median	27	29	25.5	0.193
Range	2–75	2–75	3–72
Case
Male	133	82	51	0.779
Female	87	52	35
Follow-up (months)
Median	46	49	38.5	0.031
Range	0–144	0–144	0–125
Severity of AA, n (%)
NSAA	140(64)	95(71)	45(52)	0.001
SAA	56(25)	32(24)	24(28)
VSAA	24(11)	7(5)	17(20)
RDW (%)
Median	15.5	16.7	13.8	<0.001
Range	11.4–27.9	15–27.9	11.4–14.9
Blood cell count (Median)
ANC (10^9/L, range)	0.69(0.01–3.83)	0.71(0.02–3.83)	0.51(0.01–1.97)	0.001
AMC (10^9/L, range)	0.11(0–0.52)	0.12(0–0.52)	0.08(0–0.44)	<0.001
PLT(10^9/L, range)	14(1–86)	15(2–66)	13(1–86)	0.031
HGB (g/L, range)	63(19–120)	58(19–114)	73.5(35–120)	<0.001

Figure 1. Red blood cell distribution width (RDW) level according to disease severity at diagnosis (non-severe, severe, and very severe AA).

Table 2. Uni- and multivariable Cox regression.

Variable	Univariable Cox regression			Multivariable Cox regression
	HR	95%CI	P	HR	95%CI	P
Age (years)
<35	1			1
35≤∼<55	1911	0.8–4.561	0.145	1.755	0.693–4.439	0.235
≥55	2.686	1.213–5.948	0.015	2.456	1.083–5.569	0.031
Severity
NSAA	1			1
SAA	5.728	2.176–15.078	<0.001	5.024	1.862–13.557	0.001
VSAA	29.298	10.96–78.321	<0.001	25.115	8.777–71.866	<0.001
RDW(%)
≥15	1			1
<15	2.935	1.45–5.941	0.003	1.646	0.765–3.542	0.203

Figure 2. Overall Survival according to RDW (≥15%, < 15%).

Figure 3. Progression-Free Survival according to RDW (≥15%, < 15%).

Figure 4. Overall Survival for NSAA patients according to RDW (≥15%, < 15%).

Figure 5. Overall Survival for SAA/VSAA patients according to RDW(≥15%, < 15%).